Source comparison
MOTS-c Popular in Metabolic Research: Features vs Alternatives
Mechanism AMPK activation + nuclear gene regulation via ATIC binding AMPK activation via mitochondrial complex I inhibition AMPK activation + gut microbiome modulation Sirtuin activation (AMPK-independent) MOTS-c uniquely combines cytoplasmic and nuclear metab
This comparison does not assign a generated winner or score.
- Mechanism
- AMPK activation + nuclear gene regulation via ATIC binding
- AMPK activation via mitochondrial complex I inhibition
- AMPK activation + gut microbiome modulation
- Sirtuin activation (AMPK-independent)
- MOTS-c uniquely combines cytoplasmic and nuclear metabolic control
- Tissue Specificity
- Systemic (muscle, liver, adipose, brain)
- Primarily hepatic glucose output suppression
- Intestinal and hepatic
- Variable (bioavailability-limited)
- MOTS-c's folate carrier entry allows broad tissue penetration
- Insulin Sensitivity Improvement
- 34% fasting glucose reduction in HFD mice (2018 Aging Cell)
- 25–30% reduction in clinical T2D trials
- 15–20% improvement in meta-analyses
- Minimal direct effect
- MOTS-c shows strongest preclinical insulin-sensitising effect
- Exercise Performance Impact
- 31% increase in time to exhaustion (2021 Nature Metabolism)
- No direct performance benefit
- Mixed evidence, likely placebo
- MOTS-c is the only MDP with replicated exercise performance data
- Administration Route
- Subcutaneous injection or intranasal
- Oral (high GI tolerability issues)
- Oral
- Oral (poor bioavailability)
- Injectable/intranasal delivery bypasses first-pass metabolism
- Half-Life
- ~2.5 hours (allows daily dosing)
- 4–6 hours
- 5–6 hours
- <1 hour
- Short half-life requires consistent dosing but avoids accumulation risk